Intravitreal adalimumab for refractory uveitis-related macular edema
Φόρτωση...
Ημερομηνία
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Ophthalmology
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVE: To evaluate the safety and efficacy of intravitreal adalimumab injections on refractory cystoid macular edema (CME) secondary to noninfectious uveitis. DESIGN: Prospective, noncomparative, interventional case series. PARTICIPANTS: Eight consecutive patients with controlled uveitis and chronic, refractory CME who had failed steroid treatment. INTERVENTION: Intravitreal adalimumab injections were given monthly for 3 months. MAIN OUTCOME MEASURES: Mean change in central retinal thickness (CRT) on optical coherence tomography (OCT); secondary objective was the mean change in best-corrected visual acuity (BCVA). RESULTS: Five of the eight patients completed the 6-month follow-up. For all 5 patients, the changes in BCVA from baseline to 3 months were not statistically significant (P=0.070). Similarly, the change in BCVA from baseline to 6 months was not statistically significant (P=1.0). The mean CRT at baseline was 692 microm. The changes from baseline to 3 months were not statistically significant (P=0.466); the changes from baseline to 6 months were also not statistically significant (P=0.808). We did not observe any ocular or systemic adverse effects. CONCLUSIONS: Intravitreal adalimumab showed no efficacy in improving BCVA or reducing CRT in patients with chronic uveitic macular edema.
Περιγραφή
Λέξεις-κλειδιά
Adult, Anti-Inflammatory Agents/*administration & dosage, Antibodies, Monoclonal/*administration & dosage, Antibodies, Monoclonal, Humanized, Female, Follow-Up Studies, Humans, Injections, Macular Edema/*drug therapy/etiology, Male, Middle Aged, Prospective Studies, Retina/drug effects, Retreatment, Tomography, Optical Coherence, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Uveitis/complications/*drug therapy, Visual Acuity/drug effects, Vitreous Body, Young Adult
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/20378179
http://ac.els-cdn.com/S0161642009014158/1-s2.0-S0161642009014158-main.pdf?_tid=ac28974acc4b36c6599a472e2cfefe68&acdnat=1332775403_a2264a93a717dd0775208cd825abcfa7
http://ac.els-cdn.com/S0161642009014158/1-s2.0-S0161642009014158-main.pdf?_tid=ac28974acc4b36c6599a472e2cfefe68&acdnat=1332775403_a2264a93a717dd0775208cd825abcfa7
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής